UV-stimulated riboflavin exerts immunosuppressive effects in BALB/c mice and human PBMCs

Copyright © 2024. Published by Elsevier Masson SAS..

Riboflavin (RF) as a photosensitizer has been used in corneal surgery and the inactivation of blood products. However, the effect of RF on immune cells after ultraviolet (UV) light stimulation has not been investigated. This study pioneered a novel application method of RF. Firstly, UV-stimulated RF was co-cultured with human peripheral blood mononuclear cells in vitro, and the apoptosis rate of lymphocyte subsets, cell proliferation inhibition rate and concentrations of IL-1β, IL-6, IL-10, TNF-α were assessed. UV-stimulated RF was then administered intravenously to mice via the tail vein for a consecutive period of 5 days. The levels of immunoglobulin (IgG, IgM, IgA), complement (C3, C4) and cytokines (IFN-γ, IL-4, IL17, TGF-β) were detected by ELISA. Flow cytometry was employed to analyze the populations of CD3+T, CD4+T, CD8+T and CD4+T/CD8+T cells in spleen lymphocytes of mice. The data showed that UV-stimulated RF can effectively induce apoptosis in lymphocytes, and different lymphocyte subtypes exhibited varying degrees of treatment tolerance. Additionally, the proliferative capacity of lymphocytes was suppressed, while their cytokine secretion capability was augmented. The animal experiments demonstrated that UV-stimulated RF led to a significant reduction observed in serum immunoglobulin and complement levels, accompanied by an elevation in IFN-γ, IL-17 and TGF-β levels, as well as a decline in IL-4 level. In summary, the results of both in vitro and in vivo experiments have demonstrated that UV-stimulated RF, exhibits the ability to partially inhibit immune function. This novel approach utilizing RF may offer innovative perspectives for diseases requiring immunosuppressive treatment.

Medienart:

E-Artikel

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Zur Gesamtaufnahme - volume:173

Enthalten in:

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 173(2024) vom: 24. März, Seite 116278

Sprache:

Englisch

Beteiligte Personen:

Chen, Xinghui [VerfasserIn]
Ge, Shuang [VerfasserIn]
Xiao, Pan [VerfasserIn]
Liu, Yulin [VerfasserIn]
Yu, Yang [VerfasserIn]
Liu, Yi [VerfasserIn]
Sun, Liping [VerfasserIn]
Yang, Lu [VerfasserIn]
Wang, Deqing [VerfasserIn]

Links:

Volltext

Themen:

207137-56-2
Cytokines
Immune-related diseases
Immunoglobulins
Immunosuppression
Interleukin-4
Journal Article
Peripheral blood mononuclear cells (PBMCs)
Riboflavin
TLM2976OFR
Transforming Growth Factor beta
Ultraviolet light

Anmerkungen:

Date Completed 27.03.2024

Date Revised 27.03.2024

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.biopha.2024.116278

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM368914895